CN100548278C - A kind of preparation method that improves rate of packaging microspheres of naltrexone - Google Patents
A kind of preparation method that improves rate of packaging microspheres of naltrexone Download PDFInfo
- Publication number
- CN100548278C CN100548278C CNB2007100993599A CN200710099359A CN100548278C CN 100548278 C CN100548278 C CN 100548278C CN B2007100993599 A CNB2007100993599 A CN B2007100993599A CN 200710099359 A CN200710099359 A CN 200710099359A CN 100548278 C CN100548278 C CN 100548278C
- Authority
- CN
- China
- Prior art keywords
- continuous phase
- naltrexone
- decentralized photo
- microspheres
- microsphere
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of novel preparation method that improves rate of packaging microspheres of naltrexone.New method disclosed by the invention adopts O/W type-emulsifying-solidification method, the first step: the decentralized photo that will contain naltrexone and macromolecular material glycolide-lactide copolymer joins in first's continuous phase (account for continuous phase cumulative volume 1～80%), to form O/W type Emulsion; Second step: becoming breast back certain hour to add second portion continuous phase (account for continuous phase cumulative volume 20～99%), to remove organic solvent and to make macromolecular material solidify to form microsphere.When adopting new method disclosed by the invention to prepare microsphere, compare with a step O/W type solvent emulsion volatility process and (be about to decentralized photo and join formation O/W type Emulsion in whole continuous phases, the volatilization organic solvent solidify to form microsphere), can significantly improve the envelop rate of naltrexone microsphere.
Description
Technical field
The present invention relates to a kind of novel preparation method that improves rate of packaging microspheres of naltrexone, belong to the galenic pharmacy field.
Background technology
(Naltrexone NTX) is the cyclopropyl derivatives of oxygen base morphine to naltrexone, is opioid receptor antagonists, the synthetic and research and development by du pont company in 1963.1984 as preventing that the adjuvant drug of reverting to take drugs after the opium drug detoxification from going on the market in the U.S., be that unique approval of present U.S. FDA and recommendation are used for preventing after the opiates drug rehabilitation prophylactic agent of reverting to take drugs, its drug effect is 17 times of naloxone, also can be used for the treatment of alcohol addiction at present.
The oral administration biaavailability of naltrexone is about 20%.Two kinds of dosage forms of tablet and injection are arranged at present, therapeutic scheme commonly used is oral 50mg/ days, once a day, the treatment of naltrexone need be maintained until more than not a half year, but reason owing to each side, the compliance of taking medicine is poor, and the mistake rate of the taking off height of treatment is so less interior durative action preparation of body such as the naltrexone microsphere of development medication number of times is significant.
The preparation method report of relevant naltrexone microsphere is few, [Preparation ofBiodegradable Microspheres and Matrix Devices Containing Naltrexone.Dinarvand R such as external Dinarvand, Moghadam SH, Mohammadyari-Fard L, et al.AAPS PharmSciTech 2003; 4 (3) Article34] PLA and naltrexone are dissolved in the 10mL dichloromethane, drop to 200mL and contain in the continuous phase of 0.5%PVA, room temperature condition solidifies 5h down, gets naltrexone microsphere, and envelop rate is about 70%; [a kind of naltrexone long-acting injectable microsphere composite and preparation method and application such as domestic marquis's Huimin.Hou Huimin, what Guangan, Luan Han Lignum Rhamnellae.ZL02145144.3] patent of having applied for the naltrexone long-acting injectable microsphere; the microsphere of this patent protection contains naltrexone base 1～40%, PLGA59.9～98.5%, PVA0.01～0.5%; system is dissolved in organic solvent with naltrexone base, PLGA and obtains decentralized photo; decentralized photo is added drop-wise under stirring in the PVA aqueous solution continuous phase; make naltrexone base, PLGA and PVA be condensed into microsphere, according to [development of naltrexone microsphere and Evaluation in Vivo and in Vitro such as what Guangan.What Guangan, Luan Hansen, Hou Huimin etc.Chinese Journal of Pharmaceuticals.2005,36 (6): 342-345] results reported is 25.9% by 35% drug loading that feeds intake obtained naltrexone microsphere, even the microsphere yield reaches 100%, its envelop rate also is no more than 75%.Generally speaking; A step O/W mon-galacta method is all adopted in the naltrexone microsphere preparation of domestic and foreign literature report, and envelop rate does not all reach more than 80% of pharmacopeia regulation.
Summary of the invention
The technical problem to be solved in the present invention provides a kind of novel preparation method that improves rate of packaging microspheres of naltrexone, by improving the preparation method of existing naltrexone microsphere, thereby improves the envelop rate of naltrexone microsphere.
For achieving the above object, the present invention is by the following technical solutions:
The present invention adopts O/W type emulsifying-solidification method, has been divided into two steps, the i.e. first step with common not being both of O/W mon-galacta method maximum: the solution of biodegradable pharmaceutical polymers is joined in first's continuous phase of certain volume, form O/W type Emulsion; Second step: become breast back certain hour to add second portion continuous phase again, obtain microsphere to remove organic solvent and macromolecular material is solidified.
Naltrexone itself has amphipathic, and certain dissolubility is promptly all arranged in fat solvent and aqueous solvent, adopts when a step, O/W type emulsion process prepared, and the continuous phase volume is big, has increased the diffusion of naltrexone in continuous phase, reduces envelop rate.Therefore, the volume of inventor imagination continuous phase when being reduced to breast, thus reduce the diffusion of naltrexone in continuous phase; The continuous phase volume reduces also can reduce the drug diffusion that causes to continuous phase dissolving diffusion with dichloromethane; Regulate continuous phase pH, naltrexone is under the pH condition of lipid maximum when making emulsifying, also can reduce the diffusion of naltrexone in continuous phase; Determine to add the time of residue continuous phase, farthest to reduce the diffusion of adding naltrexone after the residue continuous phase.Abovementioned technology can significantly improve the envelop rate of naltrexone microsphere.
A kind of novel preparation method that improves rate of packaging microspheres of naltrexone adopts O/W type emulsifying-solidification method to prepare microsphere, comprises the steps:
(1) be that the daltonian polylactide-co-glycolide of 5000-100000 (PLGA) joins dissolving acquisition decentralized photo solution in the decentralized photo solvent with naltrexone and molecular weight, the solution total solid concentration is 10-30%, the decentralized photo drips of solution is added in first's continuous phase of certain volume, rotating speed is 300-1000rpm during emulsifying, form O/W type Emulsion, the volume ratio of decentralized photo solution and first's continuous phase solution is 1: 1-1: 50;
(2) form behind the O/W type Emulsion 0-120 minute, join second portion continuous phase again and be cured, the curing rotating speed is 100-1000rpm, and be 3-24 hour hardening time, removes organic solvent, obtains microsphere.
Wherein, the decentralized photo solvent is selected from dichloromethane, chloroform, acetone, oxolane, dimethyl sulfoxide, ethanol or the ethyl acetate one or more;
Continuous phase is water or the aqueous solution that contains surfactant, and surfactant is selected from one or more in polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), Polyethylene Glycol (PEG), sodium polymethacrylate, sodium polyacrylate, methylcellulose, sodium carboxymethyl cellulose, the hydroxypropyl emthylcellulose;
First's continuous phase volume is the 1-80% of continuous phase cumulative volume, and second portion continuous phase volume is the 99-20% of continuous phase cumulative volume.
The molecular weight of described polylactide-co-glycolide is 10000-50000 dalton.
The preferred dichloromethane of described decentralized photo solvent.
Surfactant in the described aqueous solution that contains surfactant is a polyvinyl alcohol, and pH is that (preferred pH is 9.0 to 4.0-12.0.), mass percent concentration is 0.1-10%.
The volume ratio of decentralized photo solution and first's continuous phase solution is 1 in the described step (1): 2-1: 20; To adopt 1: 6.25 in the preferred version.
Described first continuous phase volume is the 5-50% of continuous phase cumulative volume, and second portion continuous phase volume is the 95-50% of continuous phase cumulative volume.
Described step (2) forms behind the O/W type Emulsion 10-60 minute, adds second portion continuous phase again.
The adding mode of second portion continuous phase is for once or several times adding in the described step (2), but once adding can realize improving the purpose of envelop rate.The volume that becomes the breast back to add residue continuous phase (second portion continuous phase) for the first time is 1～90% of total continuous phase volume.
Advantage of the present invention is: when adopting new method disclosed by the invention to prepare microsphere, compare with a step O/W type solvent emulsion volatility process and (be about to decentralized photo and join formation O/W type Emulsion in whole continuous phases, the volatilization organic solvent solidify to form microsphere), can significantly improve the envelop rate of naltrexone microsphere.
The invention will be further described below in conjunction with drawings and Examples, do not limit the present invention in any way, all any this areas of carrying out according to the disclosure of invention be equal to replacement, all belong to protection scope of the present invention.
Description of drawings
Fig. 1 makes the electromicroscopic photograph of microsphere for embodiment 1.
Fig. 2 makes the release in vitro curve of microsphere for embodiment 1.
Fig. 3 makes the interior release profiles of body of microsphere for embodiment 1.
The specific embodiment
Embodiment 1
Precision takes by weighing a certain amount of polylactide-co-glycolide (poly (d, l-lactic-co-glycolic acid), PLGA, polymerization ratio 75: 25, molecular weight 15000) and a certain amount of naltrexone free alkali, make theoretical drug loading be respectively 10%, 30% and 50% (seeing Table 1), add the 1.6ml dichloromethane, the vortex dissolving obtains decentralized photo under the room temperature, and making the solution total solid concentration is 25%.Adding 10ml in the 50ml beaker contains in the continuous phase (pH 9.0) of 0.2% polyvinyl alcohol, place on the magnetic agitation instrument, set rotating speed 600rpm, decentralized photo is dropped in the continuous phase, form O/W type Emulsion, be transferred to behind the 30min in the beaker that contains 90ml continuous phase, with the rotating speed stirring 5h of 300rpm, centrifugal, collect thus obtained microsphere, with distilled water wash repeatedly after, centrifugal again collection, lyophilization promptly.Thus obtained microsphere smooth in appearance rounding records envelop rate and the results are shown in Table 1.
Table 1 drug loading is to the influence of envelop rate
| Polylactide-co-glycolide (mg) | Naltrexone free alkali (mg) | Envelop rate (%) |
| 360 | 40 | 88.82 |
| 280 | 120 | 87.38 |
| 200 | 200 | 72.57 |
Embodiment 2
Precision takes by weighing 280mg polylactide-co-glycolide (polymerization ratio 75: 25, molecular weight 15000) and 120mg naltrexone free alkali, theoretical drug loading is 30%, adds the 1.6ml dichloromethane, the vortex dissolving obtains decentralized photo under the room temperature, and making the solution total solid concentration is 25%.Adding different volumes (seeing Table 2) in the 50ml beaker contains in the continuous phase (pH 9.0) of 0.2% polyvinyl alcohol, place on the magnetic agitation instrument, set rotating speed 600rpm, decentralized photo is dropped in the continuous phase, form O/W type Emulsion, be transferred to behind the 30min in the beaker that residue continuous phase (making the continuous phase cumulative volume is 100mL) is housed, with the rotating speed stirring 5h of 300rpm, centrifugal, collect thus obtained microsphere, with distilled water wash repeatedly after, centrifugal again collection, lyophilization promptly.Thus obtained microsphere smooth in appearance rounding records envelop rate and the results are shown in Table 2.
The table 2 first continuous phase volume is to the influence of envelop rate
| Polylactide-co-glycolide (mg) | Naltrexone free alkali (mg) | The first continuous phase volume (mL) | Envelop rate (%) |
| 280 | 120 | 5 | 73.47 |
| 280 | 120 | 10 | 87.38 |
| 280 | 120 | 20 | 71.92 |
Embodiment 3
Precision takes by weighing 280mg polylactide-co-glycolide (polymerization ratio 75: 25, molecular weight 15000) and 120mg naltrexone free alkali, theoretical drug loading is 30%, adds the 1.6ml dichloromethane, the vortex dissolving obtains decentralized photo under the room temperature, and making the solution total solid concentration is 25%.Adding 10ml in the 50ml beaker contains in the different pH continuous phases (seeing Table 3) of 0.2% polyvinyl alcohol, place on the magnetic agitation instrument, set rotating speed 600rpm, decentralized photo is dropped in the continuous phase, form O/W type Emulsion, be transferred to behind the 30min in the beaker that contains 90ml continuous phase, with the rotating speed stirring 5h of 300rpm, centrifugal, collect thus obtained microsphere, with distilled water wash repeatedly after, centrifugal again collection, lyophilization promptly.Thus obtained microsphere smooth in appearance rounding records envelop rate and the results are shown in Table 3.
Table 3 continuous phase pH is to the influence of envelop rate
| Polylactide-co-glycolide (mg) | Naltrexone free alkali (mg) | Continuous phase pH | Envelop rate (%) |
| 280 | 120 | 4 | 74.14 |
| 280 | 120 | 9 | 87.38 |
| 280 | 120 | 12 | 79.21 |
Embodiment 4
Precision takes by weighing 280mg polylactide-co-glycolide (polymerization ratio 75: 25, molecular weight 15000) and 120mg naltrexone free alkali, theoretical drug loading is 30%, adds the 1.6ml dichloromethane, the vortex dissolving obtains decentralized photo under the room temperature, and making the solution total solid concentration is 25%.Adding 10ml in the 50ml beaker contains in the continuous phase (pH9.0) of 0.2% polyvinyl alcohol, place on the magnetic agitation instrument, set different rotating speeds (seeing Table 4), decentralized photo is dropped in the continuous phase, form O/W type Emulsion, be transferred to behind the 30min in the beaker that contains 90ml continuous phase, with the rotating speed stirring 5h of 300rpm, centrifugal, collect thus obtained microsphere, with distilled water wash repeatedly after, centrifugal again collection, lyophilization promptly.Thus obtained microsphere smooth in appearance rounding records envelop rate and the results are shown in Table 4.
Table 4 emulsifying rotating speed is to the influence of envelop rate
| Polylactide-co-glycolide (mg) | Naltrexone free alkali (mg) | Rotating speed (rpm) | Envelop rate (%) |
| 280 | 120 | 600 | 87.38 |
| 280 | 120 | 800 | 84.52 |
| 280 | 120 | 1000 | 82.52 |
Precision takes by weighing 280mg polylactide-co-glycolide (polymerization ratio 75: 25, molecular weight 15000) and 120mg naltrexone free alkali, theoretical drug loading is 30%, adds the 1.6ml dichloromethane, the vortex dissolving obtains decentralized photo under the room temperature, and making the solution total solid concentration is 25%.Adding 10ml in the 50ml beaker contains in the continuous phase (pH9.0) of 0.2% polyvinyl alcohol, place on the magnetic agitation instrument, set rotating speed 600rpm, decentralized photo is dropped in the continuous phase, form O/W type Emulsion, be transferred in the beaker that contains 90ml continuous phase at different time (seeing Table 5), with the rotating speed stirring 5h of 300rpm, centrifugal, collect thus obtained microsphere, with distilled water wash repeatedly after, centrifugal again collection, lyophilization promptly.Thus obtained microsphere smooth in appearance rounding records envelop rate and the results are shown in Table 5.
Table 5 becomes the influence of the breast second continuous phase joining day of back to envelop rate
| Polylactide-co-glycolide (mg) | Naltrexone free alkali (mg) | Retention time behind the colostrum (min) | Envelop rate (%) |
| 280 | 120 | 0 | 44.27 |
| 280 | 120 | 15 | 72.97 |
| 280 | 120 | 30 | 87.38 |
| 280 | 120 | 60 | 63.96 |
Embodiment 6
Precision takes by weighing 280mg polylactide-co-glycolide (polymerization ratio 75: 25, molecular weight 15000) and 120mg naltrexone free alkali, theoretical drug loading is 30%, adds the 1.6ml dichloromethane, the vortex dissolving obtains decentralized photo under the room temperature, and making the solution total solid concentration is 25%.Adding 10ml in the 50ml beaker contains in the continuous phase (pH9.0) of 0.2% polyvinyl alcohol, place on the magnetic agitation instrument, set rotating speed 600rpm, decentralized photo is dropped in the continuous phase, form O/W type Emulsion, be transferred to behind the 30min in the beaker that contains different volumes (seeing Table 6) continuous phase, with the rotating speed stirring 5h of 300rpm, centrifugal, collect thus obtained microsphere, with distilled water wash repeatedly after, centrifugal again collection, lyophilization promptly.Thus obtained microsphere smooth in appearance rounding records envelop rate and the results are shown in Table 6.
The table 6 second continuous phase volume is to the influence of envelop rate
| Polylactide-co-glycolide (mg) | Naltrexone free alkali (mg) | The second continuous phase volume (mL) | Envelop rate (%) |
| 280 | 120 | 10 | 61.64 |
| 280 | 120 | 30 | 66.05 |
| 280 | 120 | 90 | 87.38 |
Embodiment 7
Precision takes by weighing 360mg polylactide-co-glycolide (polymerization ratio 75: 25, molecular weight 10000) and 40mg naltrexone free alkali, theoretical drug loading is 10%, adds 3.0ml dichloromethane and 1.0ml ethanol, the vortex dissolving obtains decentralized photo under the room temperature, and making the solution total solid concentration is 10%.Adding 8ml in the 50ml beaker contains in the continuous phase (pH4.0) of 0.1% hydroxypropyl emthylcellulose, place on the magnetic agitation instrument, set rotating speed 300rpm, decentralized photo is dropped in the continuous phase, form O/W type Emulsion, be transferred to behind the 120min in the beaker of 800ml continuous phase, with the rotating speed stirring 3h of 100rpm, centrifugal, collect thus obtained microsphere, with distilled water wash repeatedly after, centrifugal again collection, lyophilization promptly.Thus obtained microsphere smooth in appearance rounding, recording envelop rate is 72.34%.
Embodiment 8
Precision takes by weighing 225mg poly-third and hands over ketone-Acetic acid, hydroxy-, bimol. cyclic ester (polymerization ratio 75: 25, molecular weight 50000) and 225mg naltrexone free alkali, theoretical drug loading is 50%, adds the 1.5ml chloroform, the vortex dissolving obtains decentralized photo under the room temperature, and making the solution total solid concentration is 30%.Adding 30ml in the 50ml beaker contains in the continuous phase (pH9.0) of 10% Polyethylene Glycol, place on the magnetic agitation instrument, set rotating speed 300rpm, decentralized photo is dropped in the continuous phase, form O/W type Emulsion, be transferred to behind the 30min in the beaker of 30ml continuous phase, with the rotating speed stirring 24h of 200rpm, centrifugal, collect thus obtained microsphere, with distilled water wash repeatedly after, centrifugal again collection, lyophilization promptly.Thus obtained microsphere smooth in appearance rounding records envelop rate 56.79%.
Embodiment 9
Get embodiment 1 prepared microsphere electron microscope photographing, and carry out extracorporeal releasing test and vivo releasing test.
During electron microscope photographing, get microsphere a little, paste on the sample copper seat with conducting resinl, under the super-resolution field emission scanning electron microscope, observe the mode of appearance and the surface character of microsphere, and take a picture, the results are shown in Figure of description 1.
During extracorporeal releasing test, precision takes by weighing naltrexone microsphere 20mg and places the 50mL triangular flask, add 20mL release medium (pH 7.4 phosphate buffers that are heated to 37 ℃ in advance, 0.05M, contain 0.02% Tween 80), the back jog mixing of jumping a queue, placing thermoregulation in advance is 37 ℃ constant temperature oscillator, at once with the frequency vibration (the about 4cm of horizontal vibration amplitude) of 125rpm.At release the 1st, 2,4,7,10,14,21,28 and 30d, take out triangular flask, draw the uniform suspension 1mL that discharges in the triangular flask, the centrifugal 10min of 3000g gets supernatant, and the HPLC method is measured naltrexone concentration in the supernatant, draw the release in vitro curve, presentation of results book accompanying drawing 2.
During vivo releasing test, adopt the SD rat (180～200g) of different sexes SPF level.Precision takes by weighing a certain amount of microsphere, add an amount of solvent for injection (containing 5% D-mannitol, 1% sodium carboxymethyl cellulose and 0.1% Tween 80), be mixed with every milliliter of medicinal liquid that contains the 100mg microsphere, behind the suspendible, with the microsphere suspension of 1mL syringe (No. 12 syringe needles) in the back leg outside of rat subcutaneous injection 0.4mL, take out the intravital residual microsphere of animal respectively at different time points, the HPLC method is measured the naltrexone amount in the residual microsphere, calculate residual percent according to dosage, and release profiles in the drafting body, presentation of results book accompanying drawing 3.
Claims (8)
1. a preparation method that improves rate of packaging microspheres of naltrexone is characterized in that adopting O/W type emulsifying-solidification method to prepare microsphere, comprises the steps:
(1) be that the daltonian polylactide-co-glycolide of 5000-100000 joins dissolving acquisition decentralized photo solution in the decentralized photo solvent with naltrexone and molecular weight, the solution total solid concentration is 10-30%, the decentralized photo drips of solution is added in first's continuous phase of certain volume, the emulsifying rotating speed is 300-1000rpm, form O/W type Emulsion, the volume ratio of decentralized photo solution and first's continuous phase solution is 1: 1-1: 50;
(2) form behind the O/W type Emulsion 15-60 minute, join second portion continuous phase again and be cured, the curing rotating speed is 100-1000rpm, and be 3-24 hour hardening time, removes organic solvent, obtains microsphere;
Wherein, the decentralized photo solvent is selected from dichloromethane, chloroform, acetone, oxolane, dimethyl sulfoxide, ethanol or the ethyl acetate one or more;
Continuous phase is that pH is the aqueous solution that contains surfactant of 4.0-12.0, and surfactant is a polyvinyl alcohol;
First's continuous phase volume is the 1-80% of continuous phase cumulative volume, and second portion continuous phase volume is the 99-20% of continuous phase cumulative volume.
2. a kind of preparation method that improves rate of packaging microspheres of naltrexone according to claim 1 is characterized in that: the molecular weight of described polylactide-co-glycolide is 10000～50000 dalton.
3. a kind of preparation method that improves rate of packaging microspheres of naltrexone according to claim 1 is characterized in that: described decentralized photo solvent is a dichloromethane.
4. a kind of preparation method that improves rate of packaging microspheres of naltrexone according to claim 1 is characterized in that: the surfactant in the described aqueous solution that contains surfactant is a polyvinyl alcohol, and mass percent concentration is 0.1-10%.
5. a kind of preparation method that improves rate of packaging microspheres of naltrexone according to claim 1 is characterized in that: the volume ratio of decentralized photo solution and first's continuous phase solution is 1 in the described step (1): 2-1: 20.
6. a kind of preparation method that improves rate of packaging microspheres of naltrexone according to claim 1 is characterized in that: the volume ratio of decentralized photo solution and first's continuous phase solution is 1: 6.25 in the described step (1).
7. a kind of preparation method that improves rate of packaging microspheres of naltrexone according to claim 1 is characterized in that: described first continuous phase volume is the 5-50% of continuous phase cumulative volume, and second portion continuous phase volume is the 95-50% of continuous phase cumulative volume.
8. a kind of preparation method that improves rate of packaging microspheres of naltrexone according to claim 1 is characterized in that: the adding mode in the second portion continuous phase of in the described step (2) O/W Emulsion being joined is for once or several times adding.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007100993599A CN100548278C (en) | 2007-05-17 | 2007-05-17 | A kind of preparation method that improves rate of packaging microspheres of naltrexone |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007100993599A CN100548278C (en) | 2007-05-17 | 2007-05-17 | A kind of preparation method that improves rate of packaging microspheres of naltrexone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101049288A CN101049288A (en) | 2007-10-10 |
| CN100548278C true CN100548278C (en) | 2009-10-14 |
Family
ID=38781028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2007100993599A Expired - Fee Related CN100548278C (en) | 2007-05-17 | 2007-05-17 | A kind of preparation method that improves rate of packaging microspheres of naltrexone |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100548278C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011004994A (en) * | 2008-11-14 | 2011-09-28 | Y Sk Chemicals Co Ltd Ewha University Industry Collaboration Foundation | Method for preparing microspheres and microspheres produced thereby. |
| CN107412188A (en) * | 2017-09-06 | 2017-12-01 | 广州中医药大学 | Asenapine microballoon and preparation method thereof and its injection |
| WO2020080806A1 (en) * | 2018-10-15 | 2020-04-23 | Chong Kun Dang Pharmaceutical Corp. | Injectable long-acting naltrexone microparticle compositions |
| CN113546060B (en) * | 2020-04-08 | 2023-04-07 | 江苏长泰药业有限公司 | Naltrexone microspheres |
| CN111329845A (en) * | 2020-04-08 | 2020-06-26 | 江苏长泰药业有限公司 | Preparation process for improving naltrexone microsphere encapsulation rate |
| CN113995733B (en) * | 2021-09-18 | 2023-08-22 | 中国人民解放军军事科学院军事医学研究院 | Thiophene norrphine sustained-release pharmaceutical composition, preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5654008A (en) * | 1993-11-19 | 1997-08-05 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
| CN1415294A (en) * | 2002-11-07 | 2003-05-07 | 上海医药工业研究院 | Long acting injection microsphere combination of naltrexone, its preparation method and application |
| CN1946353A (en) * | 2004-04-22 | 2007-04-11 | 阿尔克姆斯第二控制治疗公司 | Naltrexone long acting formulations and methods of use |
-
2007
- 2007-05-17 CN CNB2007100993599A patent/CN100548278C/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5654008A (en) * | 1993-11-19 | 1997-08-05 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
| CN1415294A (en) * | 2002-11-07 | 2003-05-07 | 上海医药工业研究院 | Long acting injection microsphere combination of naltrexone, its preparation method and application |
| CN1946353A (en) * | 2004-04-22 | 2007-04-11 | 阿尔克姆斯第二控制治疗公司 | Naltrexone long acting formulations and methods of use |
Non-Patent Citations (2)
| Title |
|---|
| Microencapsulation by solventextraction/evaporation:reviewing the state of the art ofmicrosphere preparation process technology. Sergio Freitas et al.Journal of Controlled release,Vol.102. 2005 * |
| Preparation of Biodegradable Microspheres andMatrix Devices Containing Naltrexone. Rassoul Dinarvand et al.AAPS PharmSciTech,Vol.4 No.3. 2003 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101049288A (en) | 2007-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100548278C (en) | A kind of preparation method that improves rate of packaging microspheres of naltrexone | |
| JP4865330B2 (en) | Oral drug delivery system | |
| US20130224257A1 (en) | Method for preparing microspheres and microspheres produced thereby | |
| CN102579362B (en) | Felodipine slow-release microspheres and preparation method thereof | |
| CN111728956B (en) | Pramipexole sustained-release microspheres and preparation method thereof | |
| CN107441067A (en) | For transmitting the anti-abuse mucomembranous adhesion agent device of buprenorphine | |
| CN102316867A (en) | Amlodipine microsphere preparation, its preparation method and application | |
| US20040266813A1 (en) | Injectable sustained-release microspheres of huperzine a compoounds | |
| JP2016515523A (en) | Compositions having rheology modifiers to reduce dissolution variability | |
| CN102462680B (en) | The long-acting slow-release microsphere of thiophene promise coffee and combinations thereof thing and preparation method | |
| JP2016514692A (en) | Composition with thixotropy and enhanced dissolution reproducibility and stability | |
| CN107773528A (en) | A kind of acetic acid Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(Hor)-D-4Aph(Cbm)-Leu-Lys(iPr)-Pro-D-Ala-NH2 injection-type sustained-release implant | |
| KR20100017904A (en) | An extended-release composition comprising a somatostatin derivative in microparticles | |
| CN103142475B (en) | Exenatideacetate sustained-release microsphere preparation and preparation method thereof | |
| CN109069416A (en) | It is sustained buprenorphine microballoon (SRBM) and its application method | |
| WO2016198113A1 (en) | Process for the preparation of drug loaded microparticles | |
| CN106729717A (en) | The analogs of GLP 1 and ziconotide composition sustained-release microsphere preparation | |
| CN103637998A (en) | Sustained-release tablet containing oxycodone and rotundine | |
| CN104523605A (en) | Triptorelin microspheres and preparing method and application thereof | |
| CN1415294A (en) | Long acting injection microsphere combination of naltrexone, its preparation method and application | |
| CN103127006B (en) | Dexlansoprazole composition for injection and preparation method thereof | |
| CN101961318A (en) | Lappaconitine sustained release microspheres for injection and preparation method thereof | |
| CN1981744B (en) | Production of injection slow-releasing micropills of lycopodine and its derivative | |
| JP2001505899A (en) | Formulation in the form of a matrix material-excipient compound optionally containing an active substance | |
| CN110742872A (en) | Preparation method of naltrexone implant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091014 Termination date: 20160517 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |